

SANGUI BIOTECH INTERNATIONAL INC  
Form 8-K  
April 13, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT**  
**TO SECTION 13 OR 15 (d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): April 11, 2012

**SANGUI BIOTECH INTERNATIONAL, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Colorado**

(State or Other Jurisdiction of Incorporation)

**000-21271**  
(Commission File Number)

**84-1330732**  
(IRS Employer Identification No.)

**Alfred-Herrhausen-Str. 44, 58455 Witten, Germany**

(Address of Principal Executive Offices) (Zip Code)

**011-49-2302-915-204**

(Registrant's Telephone Number, Including Area Code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- . Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- . Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- . Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- . Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

**CE Effective**

The European Patent Office has granted a patent based on Sangui's application Therapeutically Active Wound Dressings, Production thereof, and Use of the same. The grant is effective April 11, 2012, subsequent to its official publication by the Patent Office.

SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc. ([www.otcmarkets.com](http://www.otcmarkets.com): SGBI)

A copy of the press release is included as exhibit 99.1 to this Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Sangui Biotech International, Inc.

Date: April 12, 2012

/s/ Thomas Striepe

By: Thomas Striepe

Its: President